---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-292306"
form_type: "8-K"
ticker: "IRON"
cik: "0001816736"
company_name: "Disc Medicine, Inc."
filed_at: "2023-12-11T23:59:59+00:00"
generated_at: "2026-06-07T15:01:47.543233+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Disc Medicine initial Phase 1b/2 data: DISC-0974 shows dose-dependent hepcidin reduction and Hb improvement in MF anemia

## Summary
- DISC-0974 reduced serum hepcidin >75% and increased serum iron >75% at 28 mg dose.
- 57% (4/7) of evaluable non-transfusion-dependent patients achieved ≥1.5 g/dL hemoglobin increase.
- One of two transfusion-dependent patients achieved transfusion independence per Gale Criteria.
- Hematologic activity observed regardless of concomitant JAK inhibitor use; drug generally well-tolerated.
- Data presented at ASH 2023; dose escalation ongoing with 11 evaluable subjects from three dose levels.

## SEC filing metadata
- accession: 0001193125-23-292306
- form_type: 8-K
- ticker: IRON
- cik: 0001816736
- company_name: Disc Medicine, Inc.
- filed_at: 2023-12-11T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1816736/000119312523292306/0001193125-23-292306-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1816736/000119312523292306/d644657d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-292306
- JSON: https://secwatch.observer/filing/0001193125-23-292306.json
- Plain text: https://secwatch.observer/filing/0001193125-23-292306.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.